Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers

BACKGROUND AND AIMS: Nalmefene has been approved in Europe for the treatment of alcohol dependence and subsequently recommended by the UK National Institute for Health and Care Excellence (NICE). This study examines critically the evidence base underpinning both decisions and the issues arising. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Fitzgerald, Niamh, Angus, Kathryn, Elders, Andrew, de Andrade, Marisa, Raistrick, Duncan, Heather, Nick, McCambridge, Jim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Vested Interests Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089629/
https://www.ncbi.nlm.nih.gov/pubmed/27262594
http://dx.doi.org/10.1111/add.13438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089629/
https://www.ncbi.nlm.nih.gov/pubmed/27262594
http://dx.doi.org/10.1111/add.13438

Ejemplares similares